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Abstracts / Osteoarthritis and Cartilage 20 (2012) S1–S9S4replacement (a clinical outcomemeasure of pain, physical function, and
structural damage representing need for replacement hip/knee
arthroplasty) is a step forward, but analogous measures are needed for
other OA-affected joint regions like spine and hand.
The process of deﬁning a biomarker's usefulness may be summarized
conceptually in laboratory assay performance (analytical validation),
reviewing correlation with clinical outcomes or therapeutic response
(qualiﬁcation), and deﬁning a real-life context inwhich the biomarker is
useful (utilization). For example, LDL cholesterol has high analytical
validity and extensive evidence supporting its role in atherogenesis, is
utilized in risk prediction for cardiovascular disease, and even can be
used as a surrogate endpoint for cardiovascular events with statin
interventions. Imagine then a future OA biomarker that is analytically
valid when measured in blood or urine (or even synovial ﬂuid), has
extensive relationship to cartilage repair or regeneration or pain, and
predicts risk for later development of virtual joint replacement. Imagine
as well that a future intervention will change this biomarker's levels in
a manner that correlates with and captures reduced risk for virtual joint
replacement. That is where we want to be. Yet howwill we know when
we get there?
 We ask, “Can we measure it well enough?” When an OA biomarker
can be reliably measured, we'll see publications showing little
extraneous variation and agreement among various assays and
laboratories with deﬁned international standards.
 We ask, “Does it connect rationally to the OA features we see?”
When an OA biomarker is connected reproducibly to disease
outcome and possibly intervention, we'll see abundant evidence
that a biomarker lies along a known pathogenetic pathway within
a deﬁned biological model (such as by Bradford Hill criteria),
correlates with symptoms or function or structural alteration, and
maybe captures response to an intervention.
 We ask, “How should it be used?” When an OA biomarker applies
to a speciﬁc proposed use, we'll see epidemiological studies
showing an important and clinically useful context for the
biomarker use, such as in prevention, diagnosis, treatment, or
mitigation.
Thus, with the fruits of genomic approaches to ﬁnd genes that lie along
OA pathogenetic pathways and of experimental biology studies to
deﬁne how variants confer risk, we can expect to identify biomarker
candidates to be characterized as potential OA biomarkers.
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THE RELEVANCE OF THE HUPO HUMAN PROTEOME PROJECT FOR
PROTEOMICS STUDIES OF OSTEOARTHRITIS
G.S. Omenn. Univ. of Michigan, Ann Arbor, MI
Purpose: To identify and characterize at least one protein from each of
the 20,300 human protein-coding genes. See Legrain et al., Mol. Cell
Proteomics (2011). To facilitate disease-related biomarker development.
Methods: Global collaborative Human Proteome Project (HPP), orga-
nized by the Human Proteome Organization (HUPO). Use of Proteo-
meXchange, linking data repositories EBI-PRIDE and neXtprot, ﬁle
sharing system Tranche, mass spectrometry-based Peptide Atlas and
SRM Atlas, and Ab-based Human Protein Atlas, to share data, reanalyze
mass spectrometry ﬁndings with a rigorous, standardized protocol, and
lay the foundation for protein biomarkers of health and disease.
Results: The Human Proteome Project was announced at the HUPO
World Congress in Sydney, Australia, in September 2010 and launched at
the HUPO World Congress in Geneva, Switzerland, in September 2011.
The HPP draws upon resource pillars for mass spectrometry, protein
capture, and knowledge base. There is some degree of evidence at the
protein level for about 13,000 of the 20,300 proteins. The HPP has two
large collaborative components: the chromosome-centric C-HPP, with so
far 16 national or international research teams characterizing the
proteins coded by genes on one chromosome each; and the biology and
disease-driven B/D-HPP, which has embraced the pre-existing organ-
based and bioﬂuid-based proteome projects of the past decade under the
aegis of HUPO. For example, the chromosome 17 team is annotating the
1182 proteins coded by genes on this chromosome (based on Ensembl,
SwissProt, and neXtprot), with a disease focus on breast cancer, reﬂecting
the breast cancer-associated Chr 17 genes ERBB2 (Her2), BRCA1, p53, and
GRB7. We are determining the concordance of protein identiﬁcations by
immunohistochemistry and by mass spectrometry and the tissueexpression patterns for the canonical proteins and for splice variants and
various types of post-translational modiﬁcations. Information about the
HPP is available at http://thehpp.org.
Conclusions: The combined chromosome-centric and biology and
disease-driven Human Proteome Project efforts are becoming well-
organized. The HPP will add greatly to our conﬁdent identiﬁcation of
human proteins currently not yet identiﬁed or mapped for tissue and
subcellular expression. The HPP provides a foundation for interpreting
results of proteomic biomarker studies of osteoarthritis and integrating
proteomics data with other omics platforms to relate genotype to
phenotype (Figure 1).
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SURGICAL MANAGEMENT OF OSTEOARTHRITIS: OPTIONS AND
OUTCOMES
J.N. Katz. Brigham and Women's Hosp., Boston, MA
Purpose: To review the options and outcomes of surgical management
of osteoarthritis of the knee and hip.
Methods: Review of pertinent peer reviewed literature.
Results: Arthroscopic lavage and debridement are no more efﬁcacious
than sham surgery or physical therapy in the management of osteoar-
thritis of the knee. The efﬁcacy of arthroscopic partial meniscectomy in
the management of meniscal tear in the setting of knee ostearthritis is
uncertain and requires further study. There has been little rigorous
comparison of osteotomy or unicompartmental knee arthroplasty with
nonoperative treatments for knee OA. Total joint arthroplasty is an
effective and cost effective intervention for advanced knee or hip
osteoarthritis. The utilization of total knee arthroplasty has expanded
considerably into younger and older populations, particularly patients
<65 years old. The outcomes of TKA in this population requires careful
study. New surgical approaches, devices and biomaterials are intro-
duced routinely in an effort to improve outcomes of total joint arth-
plasty. These innovations must be scrutinized carefully before
widespread adoption in order to ensure that they improve upon the
excellent short and long term outcomes achieved with existing
technology.
Conclusions:Whilecontinued research isneededurgently to optimzeuse
of these costly interventions, a growing body of evidence permits judi-
cious use of surgical interventions for osteoarthritis of the hip and knee.
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TECHNICAL DEVELOPMENTS IN GENETIC MODIFIED ANIMAL MODEL
P.M. van der Kraan. Radboud Univ., Med. Ctr., Nijmegen, Netherlands
Animal models are until now irreplaceable tools of osteoarthritis
research. Studies can make use of either spontaneous occurring oste-
oarthritis or of induced models to study the disease process. However,
the role of speciﬁc genes and proteins in osteoarthritis has made a big
step forward after the generation of transgenic animal models, mainly
in the mouse. The generation of transgenic animal models has shown
a vast development in the years since the ﬁrst transgenic mouse was
created bymicro-injection and random integration of DNA. The creation
of knock out mice, the use of tissue speciﬁc promoters, ﬂoxed mice, and
the introduction of inducible expression systems has advanced the
usability of these transgenic mice in OA research worldwide. This
workshop will focus on the latest developments in murine transgenics
and illustrate the contribution of these models to our understanding of
the OA disease process.
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BIOLOGICAL SURGICAL REPAIR
A.H. Gomoll. Brigham and Women's Hosp., Boston, MA
Articular cartilage defects are common, being encountered inmore than
half of all knee arthroscopies. While not all defects are symptomatic,
those that are can cause disability comparable to that seen in patients
awaiting knee replacement for advanced osteoarthritis. Knee replace-
ment provides good pain relief with relatively high patient satisfaction
over 70%, and 10 year survival rates of 80% to 90%. However, the
majority of these studies were conducted in older patients, ranging in
age from the late 60s to early 80s. Younger patients are less satisﬁed
with the outcome and also demonstrate higher implant failure rates. It
therefore appears reasonable to attempt delaying arthroplasty as long
as possible, especially in young patients.
